artience and Immuno-Biological Laboratories develop an ELISA kit that uses chemical synthesis additives to reduce the use of bio-derived proteins by over 90%.

artience Co., Ltd. (President and Representative Director Satoru Takashima, Chuo-ku, Tokyo) and Immuno-Biological Laboratories Co., Ltd. (President and Representative Director Tsutomu Seito, Fujioka City, Gunma Prefecture; hereafter IBL) have developed chemical synthesis additives developed by artience as alternative raw materials in ELISA kits that detect and measure specific proteins such as antigens and antibodies contained in blood samples. We succeeded in reducing the use of biologically derived proteins by more than 90%.
This product will be sold by IBL as the "sCLEC-2 ELISA Kit-IBL" starting mid-July 2026.

Image of the test kit (provided by IBL)

Sciforiem™ PL 1000 Series product image

Test kits for in vitro diagnostics and research reagents use biologically derived proteins as raw materials, but variability in quality and unstable procurement have become chronic challenges. As improvements in inspection accuracy and stable quality become increasingly demanded, the application of chemical synthetic materials has recently attracted attention as an improvement or alternative.
Since the start of the business partnership on July 1, 2025, artience and IBL have been working to develop more precise and stable in vitro diagnostic and test reagents that do not require biological proteins by combining IBL's technologies in antibodies, reagent kits, and in vitro diagnostics with artience 's polymer materials and chemical synthesis technologies.

As one of these achievements, we have adopted the artience 's "Sciforiem ™ PL 1000 Series" as an alternative ingredient to the biologically derived protein bovine serum albumin (BSA), which has been widely used as a raw material for IBL's ELISA kit measuring human soluble C-type lectin-like receptors (sCLEC-2). We developed technology that reduces BSA usage by over 90% and established a sales system from IBL. By replacing biologically derived proteins with chemical synthesis additives, it becomes possible to ensure stable quality and supply of raw materials, contributing to improved accuracy and quality stability of test kits.

artience and IBL aim to continue combining their strengths to deliver high-quality and sustainable products globally.

About artience 's Bioscience Business

artience has designated the bio field as one of its next-generation businesses in its medium-term management plan and is working to create new businesses. Centered on its core materials of colorants and polymers, it develops products such as high-sensitivity near-infrared fluorescent probes for imaging and functional polymers for in vitro diagnostic reagents. In particular, synthetic polymers used in in vitro diagnostics and research reagents have been recognized for significantly suppressing quality variation—a challenge unique to bio-derived raw materials—and improving sensitivity to antigen-antibody responses, earning a solid track record in the market.
artience group aims to improve consumers' quality of life and realize a society where people can live richly by contributing to solving challenges from early disease detection to diagnosis and treatment by providing materials and services that apply material design technologies such as colorants and polymers, as well as dispersion technologies, to the life sciences.

Related Pages

• Bioscience Solutions
  https://www. artience group.com/ja/products/solution/bioscience/index.html
• In Vitro DiagnosticsFunctional Polymers
  https://www. artience group.com/ja/products/rd/sciforiem.html
• Near-infrared fluorescence probe for high-sensitivity imaging
  https://www. artience group.com/ja/products/rd/fluorescence-probe.html

About Immuno-Biological Laboratories Co., Ltd.

Since its founding in 1982, Immuno-Biological Laboratories Co., Ltd. has been dedicated to researching the immune mechanism, "antibodies," which are essential for sustaining life in living organisms. Through proprietary antibody development technologies, we pursue the development of antibodies against proteins related to brain and nervous diseases, cancer, autoimmune diseases, and more. The IBL antibody product line includes over 1,000 types of antibodies related to Alzheimer's, lifestyle-related diseases, cancer, and more, supplying them as diagnostics, diagnostic raw materials, and research reagents to research institutions and diagnostic manufacturers such as universities and pharmaceutical companies both domestically and internationally. For more details about Immunobiology Research Institute Co., Ltd., please visit the website below.
https://www.ibl-japan.co.jp/ https://www.ibl-japan.co.jp/en/

Related Releases

• artience Signed a basic agreement withImmuno-Biological Laboratories on a business alliance in life sciences related businesses.
  https://www. artience group.com/ja/news/2025/25070102.html